Research ArticleAccepted Article
Chronic pain and assessment of pain sensitivity in patients with axial spondyloarthritis: Results from the SPARTAKUS cohort
Elisabeth Mogard, Tor Olofsson, Stefan Bergman, Ann Bremander, Lars-Erik Kristensen, Jack Kvistgaard Olsen, Johan K. Wallman and Elisabet Lindqvist
The Journal of Rheumatology December 2020, jrheum.200872; DOI: https://doi.org/10.3899/jrheum.200872
Elisabeth Mogard
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
Tor Olofsson
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
Stefan Bergman
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
Ann Bremander
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
Lars-Erik Kristensen
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
Jack Kvistgaard Olsen
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
Johan K. Wallman
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
Elisabet Lindqvist
Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Spenshult Research and Development Centre, Halmstad, Sweden; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, Copenhagen, Denmark. Supported by grants from the Faculty of Medicine, at Lund University; Region Skåne; Skåne University Hospital; Spenshult Research and Development Centre; ALF Region Skåne; the Swedish Rheumatism Association; the Anna-Greta Crafoord Foundation; the Kock Foundation; the Österlund Foundation; and the Lundgren Foundation. Conflict of interest: TO has received interview fees from Eli Lilly and provided consultancy for Merck, Sharp & Dohme (MSD) (unrelated to the present work). LEK has received consultancy and speaker’s bureau fees from AbbVie; Amgen; Biogen; Bristol-Myers Squibb (BMS); Celgene; Eli Lilly; Janssen Pharmaceuticals; Merck, Sharp & Dohme (MSD); Novartis; Pfizer; Roche; Sannofi; and UCB Pharma (unrelated to the present work). JKW has received consultancy fees from AbbVie; Celgene; Eli Lilly; Novartis; and UCB Pharma (unrelated to the present work). The remaining authors have no competing interests. Corresponding author: Elisabeth Mogard, Department of Rheumatology, Skåne University Hospital, Kioskgatan 5, SE-221 85 Lund, Sweden. E-mail: elisabeth.mogard@med.lu.se.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Chronic pain and assessment of pain sensitivity in patients with axial spondyloarthritis: Results from the SPARTAKUS cohort
Elisabeth Mogard, Tor Olofsson, Stefan Bergman, Ann Bremander, Lars-Erik Kristensen, Jack Kvistgaard Olsen, Johan K. Wallman, Elisabet Lindqvist
The Journal of Rheumatology Dec 2020, jrheum.200872; DOI: 10.3899/jrheum.200872
Accepted manuscript
Chronic pain and assessment of pain sensitivity in patients with axial spondyloarthritis: Results from the SPARTAKUS cohort
Elisabeth Mogard, Tor Olofsson, Stefan Bergman, Ann Bremander, Lars-Erik Kristensen, Jack Kvistgaard Olsen, Johan K. Wallman, Elisabet Lindqvist
The Journal of Rheumatology Dec 2020, jrheum.200872; DOI: 10.3899/jrheum.200872